Stocks TelegraphStocks Telegraph
Stock Ideas

ABT Company Profile and Key Details

NYSE : ABT

Abbott Laboratories

$94.45
-0.73-0.77%
Open: 10:13 AM
64.94
BESG ScoreESG Rating

Price Chart

Stock Price Today

Abbott Laboratories (ABT) stock declined over -0.77%, trading at $94.45 on NYSE, down from the previous close of $95.18. The stock opened at $95.03, fluctuating between $93.91 and $95.03 in the recent session.

Stock Snapshot

95.18
Prev. Close
164.51B
Market Cap
93.91
Day Low
18.13
P/E Ratio
5.21
EPS (TTM)
2.48
Cash Flow per Share
95.03
Open
1.74B
Number of Shares
95.03
Day High
99.41%
Free Float in %
22.39
Book Value
469.62K
Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing DateAccepted Date

Annual Report (10-k)

Filing DateAccepted Date

Stock Price History Chart

DateOpenHighLowCloseVolume
Jul 08, 202695.1196.1994.3095.188.58M
Jul 07, 202697.2798.1495.7495.849.68M
Jul 06, 202695.0095.9292.9995.6314M
Jul 02, 202693.4195.7491.9195.4010.64M
Jul 01, 202692.2594.0091.7792.1813.93M
Jun 30, 202693.2993.2990.6190.749.94M
Jun 29, 202694.5494.9892.6792.7110.24M
Jun 26, 202693.8695.2193.2194.1216.46M
Jun 25, 202690.6094.5690.2893.2416.7M
Jun 24, 202691.1992.9290.3090.4913.2M
Jun 23, 202688.9590.9388.7390.5311.95M
Jun 22, 202688.1588.5987.2187.8311.46M
Jun 18, 202688.6489.4487.7688.4141.96M
Jun 17, 202690.3691.5887.8788.5013.05M
Jun 16, 202689.3690.6988.8390.6211.3M
Jun 15, 202688.2689.1687.7388.6710.95M
Jun 12, 202689.6290.2987.0788.1813.66M
Jun 11, 202689.2690.3788.7689.6515.06M
Jun 10, 202691.3291.3288.6989.1711.85M
Jun 09, 202690.7392.0290.1391.2513.76M

Contact Details

Abbott Park, IL 60064-6400

United States

https://www.abbott.com224 667 6100

About Company

Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.

Company Information

Employees114000
Beta0.62
Sales or Revenue$40.11B
5Y Sales Change%0.328%
Fiscal Year EndsDecember
SectorHealthcare
IndustryMedical - Devices

Company Overview

Abbott Laboratories (NYSE:ABT) closed at $95.18 USD, losing -$0.66 (-0.69%) from the previous close of $95.84. The stock is currently mid-range between its 52-week high and low $81.97 and $137.49. With a market capitalization of about $165.79 billion, Abbott Laboratories is classified as a large-cap and shows lower-than-market volatility (beta ~0.61). Key stats such as the average daily volume over the past year has been around 13.33 million shares, volume is running light vs its 52-week average. Headquartered in Abbott Park, IL, Abbott Laboratories operates in the Healthcare sector and the Medical - Devices industry. Led by CEO Robert Ford, the company employs approximately 114,000 people and listed since March 17, 1980. Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions.

Technical Performance

Short-term trend indicators are bullishly aligned (SMA20 4.07%, SMA50 -1.48%, SMA200 -8.79%). The stock’s 14-day RSI is 56.54 (neutral), while the ATR of 2.26 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -17.69% below its high and over 10.42% above its low. Average 10-day trading volume of 11.00 million shares is below the 3-month average of 13.21 million, indicating normal recent market interest.

Valuation Metrics

Abbott Laboratories trades at a P/E ratio of 26.51, slightly below the S&P 500 average, with a price-to-sales ratio of 3.68 and a price-to-book ratio of 3.2 trading at moderately above to book value. The P/FCF stands at 22.53, also above market averages.

Dividend & Fair Value

Abbott Laboratories last paid a dividend of 2.44 per share, this equals a trailing yield of roughly 2.16%. Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $126.54. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Abbott Laboratories generated EPS of $3.72 over the past year. Five-year average earnings growth is 8.23%. Wall Street analysts project EPS growth of 10.06% annually over the next five years. The latest quarter delivered EPS of $1.15. The next quarter is forecast at $1.15. Next year's EPS is expected at $4.12. Analyst sentiment is bullish. Analyst rating data shows there are 27 Strong Buy ratings, 15 Buy ratings, 3 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $169.00 to $112.00. The high target offers 77.56% upside. The low target suggests 17.67% downside. The mean target is $136.16. This offers 43.06% upside. Abbott Laboratories earnings surprise history is a consistent trend of beating forecasts. The quarter that ended April 16, 2026, missed forecasts by 0.88%. The prior quarter beat by 0.0%. Over the last six quarters, Apple has recorded several small beats. These include 0.0% in January 22, 2025.

Shareholding & Insider Activity

Abbott Laboratories has 1.74 billion shares outstanding. The public float is 1.73 billion shares, elevated short interest at 1.41% of float. This equals 21.97 million shares. The short ratio is 1.84 days. Institutional investors hold 83.03% of the float. Insiders own 0.5%. STARKS DANIEL J holds 6.73 million shares, CAPEK JOHN M has 321.40 thousand shares and Ford Robert B has 216.20 thousand shares. Over the past six months, insider transactions show net selling. They sold 4.20 thousand shares across 6 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Abbott Laboratories generated $40.11B in revenue, or $22.93 per share. Gross margin was 55.18%, operating margin 16.15%, and net profit margin 14.27%. Returns are healthy, with ROA at 7.82% and ROE at 14.83%.
On valuation metrics, Abbott Laboratories trades at a P/E of 26.51, P/S of 3.68 and P/B of 3.20. The current ratio is 1.39 and quick ratio is 1.01. Operationally, the company’s inventory turnover is 2.82 and cash conversion cycle is 109.22 days. Debt-to-equity is 0.65, supported by a cash flow-to-debt ratio of 0.28.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Abbott Laboratories posted revenue of $40.11B, down slightly from $43.65B in the prior quarter. Gross profit was $22.13B (margin 55.18%). Operating income was $6.48B (margin 16.2%). Net income was$5.72B (EPS $3.30).
The company ended the quarter with $7.28B in cash and short-term investments, a total debt of $15.87B, and net debt of $8.98B. Total assets were $73.21B, with equity of $38.83B. Financials further reflected stability, with operating cash flow of $7.26B, free cash flow of $5.06B, and capital expenditures of - $2.20B.

Price Forecast & Outlook

Our AI price prediction model suggests that Abbott Laboratories stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 3.82%, with price expected at $98.82 by July 22, 2026, within a range of $96.99 to $100.71 3-Month Outlook: Projected fall of -5.69%, reaching $89.76 by October 06, 2026, with a range of $86.54 to $92.20. 1-Year Outlook: Projected gain of 1.62%, with price at $96.72 by July 08, 2027, within a range of $92.63 to $101.20.

Key Takeaways

Abbott Laboratories (NYSE:ABT) shares are flat -3.31% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Abbott Laboratories trading at a premium to the broader market with a P/E of 26.51. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $131.16, suggesting 37.8% upside. Our AI forecast model points to short-term strength (3.82% over two weeks), a medium-term fall (-5.69% over three months), and a longer-term gain (1.62% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Abbott Laboratories (ABT) stock price?
Abbott Laboratories (NYSE: ABT) stock price is $94.45 in the last trading session. During the trading session, ABT stock reached the peak price of $95.03 while $93.91 was the lowest point it dropped to. The percentage change in ABT stock occurred in the recent session was -0.77% while the dollar amount for the price change in ABT stock was - $0.73.
ABT's industry and sector of operation?
The NYSE listed ABT is part of Medical - Devices industry that operates in the broader Healthcare sector. Abbott Laboratories designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Who are the executives of ABT?
Mr. Joseph J. Manning
Executive Vice President of Nutritional Products
Mr. Scott Michael Leinenweber
SVice President of Licensing, Acquisitions & Ventures
Ms. Elaine R. Leavenworth
Senior Vice President and Chief Marketing & External Affairs Officer
James E. Young
Vice President and Chief Ethics & Compliance Officer
Dr. John M. Capek
Executive Vice President of Ventures
Mr. Robert B. Ford
Chairman, Pres & Chief Executive Officer
Mr. Robert E. Funck Jr.
Executive Vice President of Fin. & Chief Financial Officer
Mr. Hubert L. Allen
Executive Vice President, Gen. Counsel & Sec.
Ms. Andrea F. Wainer
Executive Vice President of Rapid & Molecular Diagnostics
Erica L. Battaglia
Vice President and Chief Ethics & Compliance Officer
Ms. Melissa Brotz
Vice President of Public Affairs & Corporation Marketing
Ms. Mary K. Moreland
Executive Vice President of HR
Mr. Jared L. Watkin
Senior Vice President of Diabetes Care
Mr. Daniel Gesua Sive Salvadori
Executive Vice President and Group Pres of Established Pharmaceuticals & Nutritional Products
How ABT did perform over past 52-week?
ABT's closing price is 16.12% higher than its 52-week low of $81.97 where as its distance from 52-week high of $137.49 is -30.77%.
How many employees does ABT have?
Number of ABT employees currently stands at 114,000.
Link for ABT official website?
Official Website of ABT is: https://www.abbott.com
How do I contact ABT?
ABT could be contacted at phone 224 667 6100 and can also be accessed through its website. ABT operates from 100 Abbott Park Road, Abbott Park, IL 60064-6400, United States.
How many shares of ABT are traded daily?
ABT stock volume for the day was 469.62K shares. The average number of ABT shares traded daily for last 3 months was 13.44M.
What is the market cap of ABT currently?
The market value of ABT currently stands at $164.51B with its latest stock price at $94.45 and 1.74B of its shares outstanding.
logo

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep

stockstelegraph

Don't have an account?

stockstelegraph

Don't have an account?

stockstelegraph

Already have an account?

stockstelegraph
Smart Screening Tools for Exceptional Returns
stockstelegraph

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!
stockstelegraph